• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?

作者信息

Toto Robert D, Rinner Steven, Ram C Venkata S

机构信息

Southwestern Medical School, University of Texas Southwestern Medical Center at Dallas, 75390, USA.

出版信息

Postgrad Med. 2004 Aug;116(2):11-6, 19-22, 48. doi: 10.3810/pgm.2004.08.1567.

DOI:10.3810/pgm.2004.08.1567
PMID:15323151
Abstract

Lowering the risk of cardiovascular disease (CVD) involves more than treatment of individual risk factors such as hypertension, diabetes, and chronic kidney disease. In this article, Drs Toto, Rinner, and Ram present an evidence-based approach to reducing CVD risk and suggest that optimal treatment with angiotensin-converting enzyme (ACE) inhibitors should be extended to a larger proportion of at-risk patients and in particular to those not previously considered candidates for use of these agents.

摘要

相似文献

1
ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?
Postgrad Med. 2004 Aug;116(2):11-6, 19-22, 48. doi: 10.3810/pgm.2004.08.1567.
2
[Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?].[肾素-血管紧张素系统阻断通过一级和二级预防降低动脉高血压所致的心血管死亡率和发病率。这条路走到尽头了吗?]
Med Clin (Barc). 2000 Jul 1;115(5):178-80. doi: 10.1016/s0025-7753(00)71500-4.
3
Arresting cardiovascular disease progression. Early treatment may counteract high risk.阻止心血管疾病进展。早期治疗可能抵消高风险。
Postgrad Med. 2004 Aug;116(2):45-8. doi: 10.3810/pgm.2004.08.1570.
4
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?血管紧张素II 1型受体阻断:厚望重归现实?
Minerva Cardioangiol. 2009 Dec;57(6):773-85.
5
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用:我们能否做得更好?
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
6
ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
Postgrad Med. 2004 Aug;116(2):31-8, 41. doi: 10.3810/pgm.2004.08.1569.
7
[The future of renin inhibition].[肾素抑制的未来]
Turk Kardiyol Dern Ars. 2009 Oct;37 Suppl 7:32-8.
8
Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.以心血管终点为指标的高血压大型试验:血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的作用
Am Heart J. 2004 Nov;148(5):747-54. doi: 10.1016/j.ahj.2004.04.037.
9
Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.高血压管理的最新进展:2型糖尿病患者的高血压治疗
J Hypertens. 2006 Jan;24(1):208-10. doi: 10.1097/01.hjh.0000198038.01387.9b.
10
Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.血管调节中的血管紧张素转换酶抑制剂的作用:超越降压作用。
Am J Ther. 2010 Jan-Feb;17(1):e11-23. doi: 10.1097/MJT.0b013e31815addd9.

引用本文的文献

1
Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease.心脏成纤维细胞与心肌细胞在健康和疾病中的复杂关系。
J Am Heart Assoc. 2021 Feb;10(5):e019338. doi: 10.1161/JAHA.120.019338. Epub 2021 Feb 15.
2
Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data.佐芬普利与氢氯噻嗪固定复方制剂治疗高血压:现有数据综述
Vasc Health Risk Manag. 2006;2(4):341-9. doi: 10.2147/vhrm.2006.2.4.341.
3
Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension.
佐芬普利加氢氯噻嗪:用于治疗轻度至中度高血压的联合疗法。
Drugs. 2006;66(8):1107-15. doi: 10.2165/00003495-200666080-00006.
4
Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.不同种族/民族单药治疗收缩压控制不佳患者使用厄贝沙坦/氢氯噻嗪固定复方制剂的情况。
J Natl Med Assoc. 2006 Apr;98(4):618-26.